Clinical Trials Logo

HIV Infections clinical trials

View clinical trials related to HIV Infections.

Filter by:

NCT ID: NCT03735849 Not yet recruiting - HIV Infections Clinical Trials

Evaluating the Safety and Pharmacokinetics of VRC-HIVMAB075-00-AB (VRC07-523LS) in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants

Start date: January 15, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and pharmacokinetics of a human monoclonal antibody (VRC07-523LS) in the sera and mucosae of healthy, HIV-uninfected adults.

NCT ID: NCT03732625 Not yet recruiting - HIV Infections Clinical Trials

Neuropsiquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study

NEARQD
Start date: January 2019
Phase: Phase 4
Study type: Interventional

Open, multicenter, non randomized, single arm, pilot trial.

NCT ID: NCT03730311 Not yet recruiting - HIV Infections Clinical Trials

Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers

Start date: December 2018
Phase: Phase 1
Study type: Interventional

A randomized, placebo-controlled, once weekly dose for four weeks, double blind study in Healthy HIV-Uninfected Volunteers (6 active; 2 placebo) with 40 mg and 80 mg in parallel followed by 120 mg after DSMB approval.

NCT ID: NCT03729778 Recruiting - HIV Infections Clinical Trials

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

Start date: January 18, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to learn more about both HIV-1 infection and advancing age, alone and in combination, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.

NCT ID: NCT03727932 Completed - HIV Infections Clinical Trials

VioOne HIV Profile Supplemental Assay

Start date: January 3, 2018
Phase: N/A
Study type: Interventional

Assessment of the sensitivity, specificity and reproducibility of the VioOne HIV Profile Supplemental Assay

NCT ID: NCT03719664 Not yet recruiting - HIV-1-infection Clinical Trials

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

ABL
Start date: November 2018
Phase: Phase 2
Study type: Interventional

The study is an adaptive, phase 2, multicenter, three-part study to establish the dosage, safety and antiviral activity of combination therapy with albuvirtide (ABT) and 3BNC117 as long-acting maintenance therapy in virologically suppressed subjects with HIV-1 infection.

NCT ID: NCT03719521 Not yet recruiting - HIV Infection Clinical Trials

Community Based Interventions to Improve HIV Outcomes in Youth: a Cluster Randomised Trial in Zimbabwe

CHIEDZA
Start date: January 2019
Phase: N/A
Study type: Interventional

A cluster randomised trial to determine the impact of an integrated community-based package of HIV services incorporating HIV testing, linkage to care and ongoing adherence support, combined with sexual and reproductive health (SRH) services and general health counselling for 16 to 24 year olds on population level HIV viral load in a high HIV prevalence setting.

NCT ID: NCT03711253 Not yet recruiting - Acute HIV Infection Clinical Trials

Empiric Treatment for Acute HIV in the ED

EMTreatED
Start date: November 2018
Phase: Phase 4
Study type: Interventional

An acceptance and feasibility study for immediate ART initiation and storage of laboratory specimens for individuals with suspected acute HIV infection who are diagnosed in one of the 7 participating emergency rooms

NCT ID: NCT03708861 Withdrawn - HIV Infection Clinical Trials

Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients

Start date: January 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to describe pharmacokinetics of maraviroc (MVC) 300 mg and atazanavir/ritonavir (ATV/r) 200/100 mg QD in HIV-infected stable patients.

NCT ID: NCT03707977 Not yet recruiting - HIV Infection Clinical Trials

Evaluating the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana (Dual bNAb Treatment in Children)

Start date: January 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the impact of two broadly neutralizing antibodies, VRC01LS and 10-1074, on the maintenance of HIV suppression in a cohort of early-treated children in Botswana.